173 related articles for article (PubMed ID: 28700521)
1. Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.
Zhang J; Dai Y; Liu Z; Zhang M; Li C; Chen D; Song H
Ther Drug Monit; 2017 Aug; 39(4):406-411. PubMed ID: 28700521
[TBL] [Abstract][Full Text] [Related]
2. CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.
Tao XR; Xia XY; Zhang J; Tong LY; Zhang W; Zhou X; Liu ZH; Song HT
Eur J Pharm Sci; 2015 Aug; 76():238-44. PubMed ID: 25976223
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
[TBL] [Abstract][Full Text] [Related]
4. Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.
Li J; Wang X; Ning C; Wang Z; Wang Y; Zheng M; Zhang S; Lu Y; Zhang Y; Li N; Chen X; Zhao D
Eur J Clin Pharmacol; 2020 Aug; 76(8):1125-1133. PubMed ID: 32382947
[TBL] [Abstract][Full Text] [Related]
5. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
[TBL] [Abstract][Full Text] [Related]
8. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.
Zhang JJ; Zhang H; Ding XL; Ma S; Miao LY
Eur J Clin Pharmacol; 2013 Apr; 69(4):807-12. PubMed ID: 23097010
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
10. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
13. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
Wang HF; Qiu F; Wu X; Fang J; Crownover P; Korth-Bradley J; Schulman S
Clin Pharmacol Drug Dev; 2014 May; 3(3):235-41. PubMed ID: 27128614
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.
Zhang W; Yuan JJ; Kan QC; Zhang LR; Chang YZ; Wang ZY; Li ZS
Eur J Anaesthesiol; 2011 Apr; 28(4):245-50. PubMed ID: 21513075
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
[TBL] [Abstract][Full Text] [Related]
16. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Xiong Y; Yuan Z; Yang J; Xia C; Li X; Huang S; Zhang H; Liu M
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):117-24. PubMed ID: 25427746
[TBL] [Abstract][Full Text] [Related]
19. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
Choi JH; Lee YJ; Jang SB; Lee JE; Kim KH; Park K
Br J Clin Pharmacol; 2007 Aug; 64(2):185-91. PubMed ID: 17391324
[TBL] [Abstract][Full Text] [Related]
20. No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.
Li M; Hu Y; Li H; Wen Z; Hu X; Zhang D; Zhang Y; Xiao J; Tang J; Chen X
Biol Pharm Bull; 2017; 40(1):88-96. PubMed ID: 28049954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
